Lower Bone Mineral Density at the Hip and Lumbar Spine in People with Psychosis Versus Controls: a Comprehensive Review and Skeletal Site-Specific Meta-analysis

Current Osteoporosis Reports

Volumn 14, Issue 6, 2016, Pages 249-259

  Gomez, Lucia ^a   Stubbs, Brendon ^b,c   Shirazi, Ayala ^a   Vancampfort, Davy ^d,e   Gaughran, Fiona ^b,c   Lally, John ^b,c,f  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f BEAUMONT HOSPITAL   (Ireland)

Author keywords

Bone mineral density; Fracture; Osteoporosis; Psychosis; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; FOLLITROPIN; HALOPERIDOL; LUTEINIZING HORMONE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THYROTROPIN; THYROXINE; ZUCLOPENTHIXOL; NEUROLEPTIC AGENT;

BONE DENSITY; BONE MASS; DUAL ENERGY X RAY ABSORPTIOMETRY; HIP; HORMONE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; LUMBAR SPINE; META ANALYSIS; MONOTHERAPY; REVIEW; SCHIZOPHRENIA; SMOKING; SYSTEMATIC REVIEW; DIAGNOSTIC IMAGING; LUMBAR VERTEBRA; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; PSYCHOSIS;

ABSORPTIOMETRY, PHOTON; ANTIPSYCHOTIC AGENTS; BONE DENSITY; HIP JOINT; HUMANS; HYPERPROLACTINEMIA; LUMBAR VERTEBRAE; OSTEOPOROSIS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SMOKING;

EID: 84989189634     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-016-0325-0     Document Type: Review

References (58)

1. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929–36.
2. Cooper C, Campion G, Melton III L. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2(6):285–9.
3. Riggs BL, Melton LR. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995;17(5):S505–11.
4. Stubbs B et al. A meta‐analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand. 2014;130(6):470–86. This study identifies an increased prevalence of osteoporosis in people with shizophrenia and highlights potential risk factors for this group.
5. Halbreich U et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med. 1995;57(5):485–91.
6. De Hert M, Detraux J, Stubbs B. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review. Expert Opinion on Drug Safety, 2016 (in press)
7. Stubbs B et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):126–33.
8. Wu C-S et al. Antipsychotic treatment and the risk of hip fracture in subjects with schizophrenia: a 10-year population-based case–control study. J Clin Psychol. 2015;76(9):1478–223. An investigation into the association between antipsychotic medication and risk of hip fracture in patients with schizophrenia.
9. Naidoo U, Goff D, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology. 2003;28:97–108.
10. Lally J et al. Clinical correlates of vitamin D deficiency in established psychosis. BMC Psychiatry. 2016;16(1):1.
11. Crews M et al. Vitamin D deficiency in first episode psychosis: a case–control study. Schizophr Res. 2013;150(2):533–7. This paper identifies low levels of vitamin D in unmedicated patients with first episode psychosis.
12. Fraser L-A et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. JAMA Intern Med. 2015;175(3):450–2.
13. Menendez ME et al. Do psychiatric comorbidities influence inpatient death, adverse events, and discharge after lower extremity fractures? Clin Orthop Relat Res. 2013;471(10):3336–48. A discussion of the increased negative impact of fractures on patients with schizophrenia.
14. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry. 2007;190(2):129–34.
15. Tseng P-T et al. Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA. Medicine. 2015;94(47), e1967.
16. Stroup DF et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–12.
17. Moher D et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.
18. DSM-IV, A.P.A.T.F.o. DSM-IV draft criteria. 1993: Amer Psychiatric Pub Incorporated
19. WHO. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
20. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–9.
21. Wyszogrodzka-Kucharska A, Rabe-Jabłońska J. Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics. Psychiatr Pol. 2004;39(6):1173–84.
22. Doknic M et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94(3):246–54.
23. Van Der Leeuw C et al. Bone mineral density as a marker of cumulative endogenous estrogen exposure: Relationship to background genetic risk of psychotic disorder. Schizophr Res. 2013;143(1):25–31.
24. Bolton JM et al. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol. 2011;31(1):56–60.
25. Taal MW et al. Usefulness of quantitative heel ultrasound compared with dual-energy X-ray absorptiometry in determining bone mineral density in chronic haemodialysis patients. Nephrol Dial Transplant. 1999;14(8):1917–21.
26. Stewart A, Kumar V, Reid DM. Long‐term fracture prediction by DXA and QUS: a 10‐year prospective study. J Bone Miner Res. 2006;21(3):413–8.
27. Kishimoto T et al. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012;25(5):415–29.
28. Hummer M, et al. Osteoporosis in patients with schizophrenia. American Journal of Psychiatry. 2005
29. Lean M, De Smedt G. Schizophrenia and osteoporosis. Int Clin Psychopharmacol. 2004;19(1):31–5.
30. Wyszogrodzka-Kucharska A, Kunert-Radek J, Rabe-Jabłońska J. Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics—risperidone and olanzapine. Psychiatr Pol. 2004;39(6):1143–55.
31. Cohen J. Statistical power analysis. Curr Dir Psychol Sci. 1992;1(3):98–101.
32. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994:1088–1101
33. Egger M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
34. Duval S, Tweedie R. Trim and fill: a simple funnel‐plot-based method of testing and adjusting for publication bias in meta‐analysis. Biometrics. 2000;56(2):455–63.
35. Wang M et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12‐month prospective study. Hum Psychopharmacol Clin Exp. 2014;29(2):183–9.
36. Maric N et al. Cumulative exposure to estrogen and psychosis: a peak bone mass, case–control study in first-episode psychosis. Schizophr Res. 2005;73(2–3):351–5.
37. Koçer E. Comparison of bone mineral density levels in young-adult patients with schizophrenia and healthy controls. Düşünen Adam: The Journal of Psychiatry and Neurological Sciences. 2011;24(4):314–20.
38. Jung D-U et al. Bone mineral density and osteoporosis risk in older patients with schizophrenia. J Clin Psychopharmacol. 2011;31(4):406–10.
39. Jung D-U et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006;67(9):1391–6.
40. Bilici M et al. The effect of chronic use of antipsychotics on the bone, breast and cervix. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology. 2011;21(2):114–21.
41. Bilici M et al. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci. 2002;112(7):817–28.
42. Altındağ Ö et al. Bone mineral density in schizophrenia patients on antipsychotics. KLINIK PSIKOFARMAKOLOJI BULTENI-Bulletin of Clinical Psychopharmacology. 2009;19(4):402–6.
43. Bergemann N et al. High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychol Med. 2008;38(08):1195–201.
44. Renn J-H et al. Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord. 2009;10(1):1.
45. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull. 2009;35(3):549–62.
46. Kishimoto T et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69(3):1478–391.
47. Eriksen E, Glerup H. Pathogenesis of osteoporosis. In: Management of fractures in severely osteoporotic bone. Springer; 2000. pp. 13–32
48. Suzuki N, Ogikubo O, Hansson T. The prognosis for pain, disability, activities of daily living and quality of life after an acute osteoporotic vertebral body fracture: its relation to fracture level, type of fracture and grade of fracture deformation. Eur Spine J. 2009;18(1):77–88.
49. Wong CC, McGirt MJ. Vertebral compression fractures: a review of current management and multimodal therapy. J Multidiscip Healthc. 2013;6:205–14. A review of multidisciplinary treatment plans for vertebral fractures.
50. Stubbs B et al. Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies. Pain. 2015;156(11):2121–31.
51. Stubbs B, Zapata-Bravo E, Haw C. Screening for osteoporosis: a survey of older psychiatric inpatients at a tertiary referral centre. Int Psychogeriatr. 2009;21(01):180–6.
52. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2):135–57.
53. Gardner-Sood P et al. Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. Psychol Med. 2015;45(12):2619–29.
54. Kanis JA et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16(2):155–62.
55. Cusano NE. Skeletal effects of smoking. Curr Osteoporos Rep. 2015;13(5):302–9. This paper discusses the significant negative impact of smoking, which has an increased prevalence amongst patients with schizophrenia, on bone health.
56. Heaney R et al. Peak bone mass. Osteoporos Int. 2000;11(12):985–1009.
57. Compston J et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009;62(2):105–8.
58. Shim J-C, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. American Journal of Psychiatry. 2007